19 and older, any sex, with Gout or Low Medication Adherence. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Medication AdherencePrimary· 3, 6, 9, and 12 months
ULT adherence, directly measured by using MEMS (Medication Event Monitoring System) Caps at 3, 6, and 9 months (assess intervention's effect) and 12 months (assess the durability of effect)
MEMSCap™ ULT MPR at 3-months
Group
Value
95% CI
Gout Storytelling Video
72.61
67.88 – 77.35
Video About Management of Another Chronic Condition
70.12
65.49 – 74.75
MEMSCap™ ULT MPR at 6-months
Group
Value
95% CI
Gout Storytelling Video
68.52
63.40 – 73.64
Video About Management of Another Chronic Condition
69.33
64.36 – 74.30
MEMSCap™ ULT MPR at 9-months
Group
Value
95% CI
Gout Storytelling Video
65.85
60.14 – 71.55
Video About Management of Another Chronic Condition
67.32
61.84 – 72.80
MEMSCap™ ULT MPR at 12-months
Group
Value
95% CI
Gout Storytelling Video
60.54
54.29 – 66.79
Video About Management of Another Chronic Condition
63.82
57.83 – 69.82
Gout FlaresSecondary· 12 months
Participant-reported total number of gout flares in the last 1 month
Group
Value
95% CI
Gout Storytelling Video
0.74
0.45 – 1.02
Video About Management of Another Chronic Condition
0.99
0.72 – 1.26
Patient SatisfactionSecondary· 12 months
Patient satisfaction with medication on the patient questionnaire (SATMED composite score), range 0-100. The SATMED-Q contains 17 items, each scored on a 5-point Likert scale. The total composite score ranges between 0 and 68. The score was converted to a percentage as recommended (=(raw score\*100)/68); higher score = more satisfaction with medication.
Group
Value
95% CI
Gout Storytelling Video
62.16
57.09 – 67.23
Video About Management of Another Chronic Condition
67.43
62.39 – 72.47
Target Serum UrateSecondary· 12 months
Serum urate with absolute value in mg/dl, as indirect measures of better ULT adherence and important gout outcomes
Group
Value
95% CI
Gout Storytelling Video
5.94
5.61 – 6.27
Video About Management of Another Chronic Condition
5.72
5.41 – 6.04
Adverse events — posted to ClinicalTrials.gov
Time frame: 1-year.
Reporting threshold: 3%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Gout Storytelling Video
Serious: 0/152 (0%)
Deaths: 4/152
Video About Management of Another Chronic Condition
The objective is to test the efficacy of a patient-centered, culturally relevant narrative intervention, or "storytelling," based on the solid conceptual foundation of the narrative communication theory and the constructs of the Health Belief Model (HBM) to improve medication adherence and outcomes in chronic diseases among African-Americans (AA), using gout as an example. Gout is a chronic disease associated with chronic symptoms and disability interrupted by intermittent acute flares, similar to Chronic Obstructive Pulmonary Disease (COPD) and Congestive Heart Failure (CHF) that leads to joint destruction if not treated appropriately. Due to the intermittently symptomatic nature of chronic conditions, patients often don't perceive disease severity and susceptibility to disease complications, and, therefore, may not balance the barriers and benefits to medication adherence. Storytelling in the patients' own voices has the power to directly and more effectively confront a patient's barriers to medication adherence, reinforce the benefits and provide useful cues to action. Storytelling promotes patient engagement when the patient identifies with the storyteller and can lead to a patient's recognition of the need to treat the condition and improve health outcomes, as shown by a meaningful improvement in blood pressure in a recent clinical trial in AAs with hypertension. The success of this project, combined with other published data, will represent a major step toward demonstrating the effectiveness of storytelling to improve medication adherence in chronic diseases and will address two VA research priority areas, i.e., health care disparities and health care delivery.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout
· Phase 3
· recruiting
NCT07367971 — Drug-Drug Interaction Study of ABP-671 in Gout Patients
· Phase 1
· recruiting
NCT07346079 — Purified Cortrophin® Gel Efficacy and Safety Study of 2 Dose Levels in Patients With Acute Gout Flares
· Phase 4
· recruiting
NCT07089875 — A Study of Dotinurad Versus Allopurinol in Participants With Gout
· Phase 3
· recruiting
NCT05507723 — Tight Control of Gouty Arthritis Compared to Usual Care
· NA
· recruiting
Other VA Office of Research and Development trials
Trials by the same sponsor.
NCT07456150 — Personalizing Veteran Pain Care: Adapting Coaching Interventions to Support Maintenance of Self-Care
· Phase 1
· not yet recruiting
NCT06746727 — The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veteran
· NA
· not yet recruiting
NCT07362576 — Perinatal Peer Support for Veterans With Serious Mental Illness
· NA
· not yet recruiting
NCT06766331 — Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
· NA
· not yet recruiting
NCT07397195 — ACT for Veterans With IBD and Mental Health Challenges
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by VA Office of Research and Development
Last refreshed: 17 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02741700.